Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Acquisitions & Divestments (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Change in Acquisitions & Divestments for 6 consecutive years, with $69.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 33.26% to $69.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $316.2 million, a 48.3% decrease, with the full-year FY2025 number at $316.2 million, down 48.3% from a year prior.
  • Change in Acquisitions & Divestments was $69.5 million for Q4 2025 at Relay Therapeutics, down from $97.8 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $386.2 million in Q1 2021 to a low of $18.1 million in Q1 2022.
  • A 5-year average of $123.0 million and a median of $100.9 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: tumbled 95.31% in 2022, then soared 867.09% in 2023.
  • Relay Therapeutics' Change in Acquisitions & Divestments stood at $35.2 million in 2021, then skyrocketed by 419.21% to $183.0 million in 2022, then grew by 7.43% to $196.6 million in 2023, then tumbled by 47.07% to $104.1 million in 2024, then crashed by 33.26% to $69.5 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Change in Acquisitions & Divestments are $69.5 million (Q4 2025), $97.8 million (Q3 2025), and $84.1 million (Q2 2025).